trial

Effects of Eszopiclone on Sleep and Memory in Schizophrenia

NCTId NCT01641900
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 59 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2012-07
Primary completion
2015-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
eszopiclone

Sponsors

Massachusetts General HospitalLead Sponsor
Beth Israel Deaconess Medical CenterCollaborator
Mclean HospitalCollaborator

Investigators

1
Dara S Manoach, Ph.D.Principal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
59
Phase
NA
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
eszopiclone
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Beth Israel Deaconess Medical Center
company
Mclean Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dara S Manoach, Ph.D.
person